FRANKFURT: BioNTech, the first in the race to produce evidence of a working COVID-19 vaccine, is planning to price the two-shot regimen below"typical market rates" and would differentiate pricing between countries or regions.
and which has yet to win regulatory approval, would reflect the financial risks that its private sector investors have incurred."We've tried to pursue a balanced approach that recognises that innovation requires capital and investment so we plan to price our vaccine well below typical market rates, reflecting the situation that we're in, and with the goal to ensure broad-based access around the world," Richardson said at the FT event.
The vaccine was on Monday shown to be 90 per cent effective, based on preliminary trial results, a key milestone in the war against a virus that has killed over a million people and battered the world's economy.In July Pfizer had agreed with the US government the supply of 100 million doses of its potential vaccine at a price of US$39 for a two-dose immunisation, or US$19.50 per dose, with the option to sell another 500 million doses under conditions to be negotiated separately.
Richardson also said that the two partners' goal to supply 1.3 billion doses in 2021 would be the result of a ramping-up efforts well into the second half of next year.